Blog
RSS FeedPosted by Michael Wonder on 12 Sep 2022
Nomination for an early re-entry resubmission - what exactly does it mean?
12 September 2022 - We compare and contrast the submissions nominated by the PBAC in March for an early re-entry ...
Posted by Michael Wonder on 02 Jun 2022
Hope for change after PHARMAC independent review
2 June 2022 - A woman who had her bowel removed while she waited for drugs that would probably have ...
Posted by Michael Wonder on 01 Jun 2022
Government response to independent PHARMAC review
1 June 2022 - The Government has released its response to the recommendations of the final report of the independent ...
Posted by Michael Wonder on 29 May 2022
Application accompanying data collection in the case of market access for several active substances in a class: IQWiG presents a concept
27 May 2022 - The institute recommends platform studies under a master's protocol. ...
Posted by Michael Wonder on 10 May 2022
Calls for Health Minister to release final report from PHARMAC review
11 May 2022 - Health Minister Andrew Little is facing calls to release the final report from a review of ...
Posted by Michael Wonder on 19 Jan 2022
UK’s NICE to launch sweeping changes to drug assessments to be faster, more agile
19 January 2022 - The health technology assessment body has been under pressure from drugmakers and patient groups for years to ...
Posted by Michael Wonder on 19 Apr 2021
NICE launches ambitious strategy to provide quicker access to new treatments and innovations
19 April 2021 - NICE will transform key elements of its approach to ensure efficiency and speed while maintaining robust, trusted ...
Posted by Michael Wonder on 30 Mar 2021
NICE methods and process review aims to create fertile ground for innovation
29 March 2021 - The way NICE reviews new medicines is about to go through its biggest change in years – ...
Posted by Michael Wonder on 01 Oct 2020
New procedures for CADTH drug reimbursement reviews
30 September 2020 - CADTH initiated stakeholder consultations in June 2020 on proposals to align the procedure for its drug ...
Posted by Michael Wonder on 16 Jul 2020
Mallinckrodt and Terumo BCT announce positive recommendations for public funding of Uvadex (methoxsalen) for ECP administration with the Therakos CE
13 July 2020 - In a rare dual-review process, two independent advisory committees to the Australian Minister for Health recommend reimbursement ...
Posted by Michael Wonder on 10 Jul 2020
Proposal to modify PHARMAC’s approach to competitive procurement
10 July 2020 - PHARMAC is proposing to standardise the way that it contracts for pharmaceuticals as a result of ...
Posted by Michael Wonder on 25 Jun 2020
Consultation on CADTH’s drug reimbursement review procedures
25 June 2020 - CADTH is inviting stakeholder feedback on a revised procedure for its drug reimbursement review processes (i.e., pan-Canadian ...
Posted by Michael Wonder on 30 Apr 2020
Procedure Guidance for standardised redactions to PBAC Public Summary Documents
30 April 2020 - The PBAC has indicated its preference for greater transparency to be introduced in PSDs through a ...
Posted by Michael Wonder on 04 Mar 2020
Revised procedure for the sponsor review of initial CADTH pCODR reports
4 March 2020 - Initial CADTH pCODR reports will now be issued to the sponsor four business days before the target ...
Posted by Michael Wonder on 09 Jan 2020
Alignment of terminology
9 January 2020 - CADTH is aligning the terminology in the single drug review processes as follows: ...